DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,511 filers reported holding DANAHER CORPORATION in Q4 2019. The put-call ratio across all filers is 1.66 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,042,344 | +14.4% | 40,477 | +10.7% | 0.10% | +17.9% |
Q2 2023 | $8,778,480 | -21.9% | 36,577 | -17.9% | 0.08% | -27.6% |
Q1 2023 | $11,235,187 | -4.4% | 44,577 | +0.6% | 0.12% | -5.7% |
Q4 2022 | $11,758,106 | +17.9% | 44,300 | +14.8% | 0.12% | +8.8% |
Q3 2022 | $9,969,994 | -76.4% | 38,600 | -73.2% | 0.11% | -71.4% |
Q1 2022 | $42,240,000 | +47.7% | 144,000 | +65.7% | 0.40% | +102.6% |
Q4 2021 | $28,591,000 | +9.1% | 86,900 | +0.9% | 0.20% | -27.2% |
Q3 2021 | $26,212,000 | +9.6% | 86,100 | -3.4% | 0.27% | +14.0% |
Q2 2021 | $23,911,000 | +18.8% | 89,100 | -0.3% | 0.24% | +19.3% |
Q1 2021 | $20,122,000 | +1.3% | 89,400 | 0.0% | 0.20% | -5.3% |
Q4 2020 | $19,859,000 | +295.8% | 89,400 | +283.7% | 0.21% | +264.9% |
Q3 2020 | $5,017,000 | +80.7% | 23,300 | +48.4% | 0.06% | +72.7% |
Q2 2020 | $2,776,000 | +47.5% | 15,700 | +15.4% | 0.03% | +26.9% |
Q1 2020 | $1,882,000 | -9.8% | 13,600 | 0.0% | 0.03% | +18.2% |
Q4 2019 | $2,087,000 | -88.3% | 13,600 | -89.0% | 0.02% | -89.1% |
Q3 2019 | $17,866,000 | +229.8% | 123,700 | +226.4% | 0.20% | +225.8% |
Q2 2019 | $5,417,000 | +508.0% | 37,900 | +362.2% | 0.06% | +520.0% |
Q3 2018 | $891,000 | -63.0% | 8,200 | -66.4% | 0.01% | -66.7% |
Q2 2018 | $2,408,000 | -85.6% | 24,400 | -85.3% | 0.03% | -87.8% |
Q2 2016 | $16,726,000 | -28.7% | 165,600 | -34.4% | 0.25% | -29.9% |
Q4 2015 | $23,450,000 | +96.5% | 252,479 | +80.3% | 0.35% | +91.8% |
Q3 2015 | $11,931,000 | +953.0% | 140,017 | +957.3% | 0.18% | +976.5% |
Q2 2015 | $1,133,000 | -54.7% | 13,243 | -55.1% | 0.02% | -55.3% |
Q1 2015 | $2,502,000 | -0.3% | 29,475 | +0.7% | 0.04% | -2.6% |
Q4 2014 | $2,509,000 | -77.6% | 29,278 | -80.1% | 0.04% | -78.9% |
Q3 2014 | $11,188,000 | -44.2% | 147,251 | -42.2% | 0.18% | -46.8% |
Q2 2014 | $20,054,000 | +5.3% | 254,715 | +0.3% | 0.35% | -3.1% |
Q1 2014 | $19,044,000 | -1.3% | 253,917 | +1.6% | 0.36% | -6.8% |
Q4 2013 | $19,301,000 | +27.6% | 250,012 | +14.5% | 0.38% | +18.8% |
Q3 2013 | $15,132,000 | +2.3% | 218,297 | -6.6% | 0.32% | +16.1% |
Q2 2013 | $14,796,000 | – | 233,744 | – | 0.28% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |